Literature DB >> 14676462

Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry.

Zdenek Sumník1, Christof Land, Gabriele Rieger-Wettengl, Frederike Körber, Angelika Stabrey, Eckhard Schoenau.   

Abstract

OBJECTIVE: Bisphosphonates are effectively used in treatment for primary osteoporosis in children. In the present study, we quantitatively evaluated the effect of pamidronate treatment on lumbar vertebrae in children with primary osteoporosis using radiographic morphometry.
METHODS: Paired lateral radiographs of the lumbar spine were obtained before and after pamidronate treatment in 5 children with primary osteoporosis. To characterize vertebral deformities, specific morphometrical ratios were calculated for vertebral bodies L1-L4.
RESULTS: Significant reshape of lumbar vertebrae was observed: the concavity index (middle-anterior ratio) decreased from 55 to 36% (p = 0.006), and the anterior-posterior ratio (used as a surrogate of wedge deformity) decreased from 25 to 11% (p = 0.001).
CONCLUSIONS: Pamidronate treatment significantly influences the restoration of vertebral fractures in children with primary osteoporosis. The present study demonstrates that radiographic morphometry is a suitable tool for quantitative assessment of the vertebral deformities in childhood. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14676462     DOI: 10.1159/000075589

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  13 in total

1.  [Bisphosphonate therapy for children and adolescents with primary and secondary osteoporotic diseases].

Authors:  O Semler; C Land; E Schönau
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

Review 2.  Pediatric Osteoporosis: Diagnosis and Treatment Considerations.

Authors:  Edoardo Marrani; Teresa Giani; Gabriele Simonini; Rolando Cimaz
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

3.  Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients.

Authors:  Giampiero I Baroncelli; Francesco Vierucci; Silvano Bertelloni; Paola Erba; Elisa Zampollo; Maria Rita Giuca
Journal:  J Bone Miner Metab       Date:  2013-04-03       Impact factor: 2.626

4.  The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.

Authors:  A M Sbrocchi; F Rauch; P Jacob; A McCormick; H J McMillan; M A Matzinger; L M Ward
Journal:  Osteoporos Int       Date:  2012-11       Impact factor: 4.507

Review 5.  Osteogenesis imperfecta: pathophysiology and treatment.

Authors:  Heike Hoyer-Kuhn; Christian Netzer; Oliver Semler
Journal:  Wien Med Wochenschr       Date:  2015-06-09

Review 6.  Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.

Authors:  J Thornton; D M Ashcroft; M Z Mughal; R A Elliott; T W O'Neill; D Symmons
Journal:  Arch Dis Child       Date:  2006-05-11       Impact factor: 3.791

Review 7.  Drug Treatment of Low Bone Mass and Other Bone Conditions in Pediatric Patients.

Authors:  Stefania Costi; Teresa Giani; Francesco Orsini; Rolando Cimaz
Journal:  Paediatr Drugs       Date:  2022-01-11       Impact factor: 3.022

8.  Observer agreement in pediatric semiquantitative vertebral fracture diagnosis.

Authors:  Kerry Siminoski; Brian Lentle; Mary Ann Matzinger; Nazih Shenouda; Leanne M Ward
Journal:  Pediatr Radiol       Date:  2013-12-10

Review 9.  Bisphosphonate treatment for children with disabling conditions.

Authors:  Alison M Boyce; Laura L Tosi; Scott M Paul
Journal:  PM R       Date:  2013-12-22       Impact factor: 2.298

Review 10.  Bisphosphonate therapy for children and adolescents with secondary osteoporosis.

Authors:  L Ward; A C Tricco; P Phuong; A Cranney; N Barrowman; I Gaboury; F Rauch; P Tugwell; D Moher
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.